Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
Seven future blockbuster drugs to look out for in 2019AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch Share XSeven future blockbuster drugs to look out for in 2019https://pharmaphorum.com/news/seven-future-blockbuster-drugs-to-look-out-for-in-2019/
